Item 7.01.  Regulation FD Disclosure.

 

The Company’s executive officers intend to conduct meetings with investors, stockholders and analysts and at investor conferences on or after November 5, 2007.  A copy of the portion of the presentation materials to be used at those meetings and from time to time thereafter that includes additional information not previously furnished as part of Company presentation materials is filed as Exhibit 99.1 hereto.  The Company does not intend to file any update of these or any other presentation materials.  The fact that these presentation materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials.

 

Item 9.01  Financial Statements and Exhibits.

 

(d)         Exhibits

 

The following exhibit is filed with this Current Report on Form 8-K:

 

Exhibit No.

 

Description

99.1

 

Tapestry Pharmaceuticals, Inc. investor presentation materials to be used by the Company’s executive officers at meetings with investors, stockholders and analysts and at investor conferences beginning on or after November 5, 2007, and to be used from time to time thereafter.

 

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 5, 2007

TAPESTRY PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Gordon Link

 

 

Name:

Gordon Link

 

Title:

Senior Vice President, Chief Financial
Officer

 


 

INDEX TO EXHIBITS

 

Exhibit No.

 

Description

99.1

 

Tapestry Pharmaceuticals, Inc. investor presentation materials to be used by the Company’s executive officers at meetings with investors, stockholders and analysts and at investor conferences beginning on or after November 5, 2007, and to be used from time to time thereafter.